Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 known ✓ | Q9ULD8 | 1/20 | 0.47 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.41 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.41 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.41 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | TAS2R38 | P59533 | 2/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6761971 | 1.00 | KCNH3 (0.47) | KCNH3PHGDHTSHRIDO1HSD17B10 | |
| SCHEMBL44951 | 0.97 | — | — | |
| Fluoride SCHEMBL28139765 | 0.94 | PHGDH (0.46) | KCNH3PHGDHTSHRIDO1HSD17B10 | |
| SCHEMBL28771750 | 0.94 | PHGDH (0.46) | KCNH3PHGDHTSHRIDO1HSD17B10 | |
| Bicarbonate SCHEMBL10803241 | 0.90 | TSHR (0.50) | KCNH3TSHRHSD17B10ALDH1A1NAPRT | |
| SCHEMBL11178475 | 0.87 | TSHR (0.67) | KCNH3PHGDHTSHRIDO1HSD17B10 | |
| Acetic Acid SCHEMBL28217523 | 0.87 | NAPRT (0.54) | TSHRHSD17B10ALDH1A1NAPRTALOX15 | |
| SCHEMBL5947069 | 0.87 | ALDH1A1 (0.62) | KCNH3TSHRHSD17B10ALDH1A1TDP1 | |
| SCHEMBL9241215 | 0.87 | KCNH3 (0.43) | KCNH3PHGDHTSHRIDO1HSD17B10 | |
| Formic Acid SCHEMBL29077132 | 0.85 | ALDH1A1 (0.44) | KCNH3PHGDHTSHRIDO1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330448-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | Atherogenics, Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| CN-113493430-B | Intermediate of beraprost and salt thereof and preparation method thereof | 江西科睿药业有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-118496185-A | Intermediate of beraprost and salt thereof and preparation method thereof | 江西科睿药业有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240246908-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2024-07-25 | — | — | US | disclosed |
| WO-2022139304-A1 | NOVEL QUINAZOLINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF | 한미약품 주식회사 | 2022-06-30 | — | — | WO | disclosed |
| CN-113493430-A | Intermediate of beraprost and salt thereof and preparation method thereof | 上海时莱生物技术有限公司 | 2021-10-12 | — | — | CN | disclosed |
| EP-2604256-B1 | Multi layer coatings | HEXAL AG (DE) | 2016-04-13 | — | — | EP | disclosed |
| CN-101903494-B | Photoalignment composition | ROLIC AG (CH) | 2016-03-02 | — | — | CN | disclosed |
| EP-2604256-A1 | Multi layer coatings | Hexal AG (DE) | 2013-06-19 | — | — | EP | disclosed |
| US-20120082721-A1 | Enteric coating | H E X A L AKTIENGESELLSCHAFT (DE) | 2012-04-05 | — | — | US | disclosed |
| US-6638534-B1 | High speed release; coating of acrylic, maleic or polyvinyl polymer; inflammable bowel syndrome, Crohn*s disease | TANABE SEIYAKU CO., LTD. (JP) | 2003-10-28 | — | — | US | disclosed |
| EP-1353648-A2 | MICROPARTICLES OF BIODEGRADABLE POLYMER ENCAPSULATING A BIOLOGICALLY ACTIVE SUBSTANCE | Debio Recherche Pharmaceutique S.A. (CH) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002058671-A1 | BURST FREE PHARMACEUTICAL MICROPARTICULES | DEBIO RECHERCHE PHARMACEUTIQUE S.A. (CH) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058672-A2 | MICROPARTICLES OF BIODEGRADABLE POLYMER ENCAPSULATING A BIOLOGICALLY ACTIVE SUBSTANCE | DEBIO RECHERCHE PHARMACEUTIQUE S.A. (CH) | 2002-08-01 | — | — | WO | disclosed |
| EP-1196148-A1 | PROCESS FOR MICROENCAPSULATION OF WATER SOLUBLE SUBSTANCES | Debio Recherche Pharmaceutique S.A. (CH) | 2002-04-17 | — | — | EP | disclosed |
| EP-1101490-A1 | PREPARATION CAPABLE OF RELEASING DRUG AT TARGET SITE IN INTESTINE | TANABE SEIYAKU CO., LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000062761-A1 | PROCESS FOR MICROENCAPSULATION OF WATER SOLUBLE SUBSTANCES | DEBIO RECHERCHE PHARMACEUTIQUE S.A. (CH) | 2000-10-26 | — | — | WO | disclosed |
| CN-1053189-C | pyridazino quinoline compounds | ZENECA LTD (GB) | 2000-06-07 | — | — | CN | disclosed |
| CN-1138332-A | Pyridazinoquinoline compounds | ZENECA LTD (GB) | 1996-12-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246908-A1 | TEAD INHIBITORS | TEAD3, TEAD1, TEAD2 | KCNH3 141/4885PTGS1 324/4885SLC6A2 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.